本次收购将实现双方优势互补。一方面，威高血净可借助威高普瑞在医药包材领域的技术积累与产品布 局，将产品线从血液净化制品拓展至医药包材赛道，实现多元化经营，降低单一业务领域的政策与市场 风险。另一方面，威高普瑞积累的丰富生物制药客户资源，可为威高血净生物制药滤器业务提供现成的 销售渠道，实现技术储备与市场渠道的双向赋能，共同开拓生物制药上游市场。 从行业背景来看，此次收购契合产业发展趋势。当前国内生物制药产业快速增长，弗若斯特沙利文数据 显示，2024年中国生物药市场规模达5348亿元，预计2032年将增至1.13万亿元，对应的医药包材及生物 制药上游耗材需求同步扩张。与此同时，生物制药上游供应链国产化进程加速，政策支持与市场需求双 重驱动下，具备技术优势的本土企业迎来发展机遇。威高血净通过此次收购，有望快速切入高增长赛 道，提升综合竞争力。 作为本次交易的标的，威高普瑞的经营状况与行业地位受到关注。公开信息显示，威高普瑞成立于2018 年，专注于预灌封给药系统及自动安全给药系统等医药包材业务，致力于为全球生物制药企业提供一站 式药品递送解决方案。财务数据显示，截至2025年6月30日，威高普瑞资产总计34.2 ...

威高血净表示，此次收购核心在于实现业务多元化拓展与技术渠道协同。 本次收购将实现双方优势互补。一方面，威高血净可借助威高普瑞在医药包材领域的技术积累与产品布 局，将产品线从血液净化制品拓展至医药包材赛道，实现多元化经营，降低单一业务领域的政策与市场 风险。另一方面，威高普瑞积累的丰富生物制药客户资源，可为威高血净生物制药滤器业务提供现成的 销售渠道，实现技术储备与市场渠道的双向赋能，共同开拓生物制药上游市场。 从行业背景来看，此次收购契合产业发展趋势。当前国内生物制药产业快速增长，弗若斯特沙利文数据 显示，2024年中国生物药市场规模达5348亿元，预计2032年将增至1.13万亿元，对应的医药包材及生物 制药上游耗材需求同步扩张。与此同时，生物制药上游供应链国产化进程加速，政策支持与市场需求双 重驱动下，具备技术优势的本土企业迎来发展机遇。威高血净通过此次收购，有望快速切入高增长赛 道，提升综合竞争力。 1月5日晚，威高血净（603014）发布公告，拟以发行股份的方式收购山东威高普瑞医药包装有限公司 （简称"威高普瑞"）100%股权，此次交易标的资产评估值为85.11亿元，交易构成重大资产重组。交易 完成后 ...

Core Viewpoint - Shandong Weigao Blood Purification Products Co., Ltd. announced its 2025 semi-annual profit distribution plan, detailing cash dividends to shareholders [1] Summary by Categories Profit Distribution - The total share capital for the profit distribution is 417,754,066 shares, with a cash dividend of 0.15756 yuan per share (including tax), amounting to a total cash dividend of 65,821,330.64 yuan [1] Key Dates - The record date for shareholders is October 23, 2025, while the ex-dividend date and cash dividend payment date is October 24, 2025 [1] Taxation Details - The announcement includes tax deduction details for different types of shareholders, such as individual and fund shareholders being taxed based on holding period, and QFII and Shanghai Stock Connect investors being subject to a 10% withholding tax [1]

Core Viewpoint - The board of directors' compensation and assessment committee of Shandong Weigao Blood Purification Products Co., Ltd. has reviewed and approved the 2025 restricted stock incentive plan, confirming its compliance with relevant laws and regulations, and asserting that it does not harm the interests of the company and its shareholders [1][2]. Summary by Relevant Sections - The incentive plan adheres to the provisions of the Company Law, Securities Law, and the Management Measures for Equity Incentives, ensuring that the granting and lifting of restrictions on the restricted stocks do not violate any legal or regulatory requirements [1]. - The plan specifies conditions under which equity incentives cannot be implemented, including negative audit opinions on financial reports, failure to distribute profits according to legal and regulatory requirements, and other situations recognized by the China Securities Regulatory Commission [1][2]. - The eligibility criteria for incentive recipients are in line with the Management Measures, ensuring that the plan is legally valid and that the interests of employees and shareholders are aligned, which is expected to enhance employee motivation and company performance [2].

Group 1 - Smart factories are the main carriers of smart manufacturing and are the primary battleground for the digital transformation and intelligent upgrade of the manufacturing industry [1][2] - The list of advanced smart factories in Sichuan for 2025 has been officially announced, including 104 factories such as Chengdu Qingshan Likang Pharmaceutical Co., Ltd. and Tongwei Solar (Kantong) Co., Ltd. [1][2] - The advanced smart factories recognized cover six major advantageous industries in Sichuan, focusing on digital transformation and networked collaboration [2][3] Group 2 - The Ministry of Industry and Information Technology has established a gradient cultivation system for smart factories, categorized into four levels: basic, advanced, excellent, and leading [2] - Longhua Holding Group has eight smart factories listed, with significant improvements in production efficiency, such as a 67% increase in the production efficiency of circuit boards [3] - The next steps for Sichuan include systematic and large-scale promotion of smart factory construction, development of smart products and equipment, and deepening applications of artificial intelligence [3]

Group 1 - The core focus is on strengthening the connection between banks and enterprises, guiding credit resources towards the real economy, especially the manufacturing sector [1] - As of the end of April, the total loan balance in Weihai reached 623.15 billion yuan, with a growth rate of 5.75%. The manufacturing loan balance was 75.57 billion yuan, growing by 6.83%, which is 1.08 percentage points higher than the overall loan growth rate [1] - Weihai's financial bureau has established three lists: the financing needs of manufacturing enterprises, applicable bank credit products, and financial policies to benefit enterprises [1] Group 2 - Six bank-enterprise connection activities have been organized this year, resulting in financing of 27.6 billion yuan. Future plans include targeted industry connections and quarterly activities in various districts [2] - A total of 2,751 financing needs from enterprises and key projects have been addressed, solving financing issues amounting to 19.93 billion yuan [2] - The People's Bank of China has introduced a comprehensive monetary policy package with ten measures, aimed at increasing credit to the manufacturing sector [3] Group 3 - The focus will also be on optimizing the operation of financial policies and expanding direct financing through stock and bond markets for manufacturing enterprises [3] - The successful listing of Shandong Weigao Blood Purification Products Co., Ltd. on the Shanghai Stock Exchange marks a significant milestone, being the first domestic listed company in the province for 2025 [3]

Core Viewpoint - Shandong Weigao Blood Purification Products Co., Ltd. has received approval for its initial public offering (IPO) of A-shares and will be listed on the main board, with the issuance price set at 26.50 yuan per share and a total of 41,139,407 shares to be issued [1][2]. Issuance Details - The IPO will consist of a combination of strategic placement, offline issuance, and online issuance, with the initial strategic placement amounting to 4,113,940 shares, representing 10% of the total issuance [1][2]. - The final strategic placement quantity was adjusted to 1,772,075 shares, approximately 4.31% of the total issuance, with the difference being allocated to offline issuance [2][3]. Subscription and Allocation - The offline issuance quantity after the strategic placement adjustment is 28,259,832 shares, accounting for 71.78% of the remaining shares, while the online issuance quantity is 11,107,500 shares, representing 28.22% [2][3]. - The initial effective subscription multiple for the online issuance was approximately 7,518.35 times, leading to the activation of the allocation mechanism, redistributing 15,747,000 shares from offline to online issuance [3]. Financial Statistics - The total amount raised from the online investors was approximately 707.77 million yuan, with 26,708,402 shares subscribed [8]. - The offline investors subscribed for 12,512,137 shares, totaling approximately 331.57 million yuan [8]. Underwriting and Fees - The total issuance costs are approximately 112.30 million yuan, including underwriting and advisory fees of 74.18 million yuan, audit and verification fees of 17.88 million yuan, and legal fees of 8.49 million yuan [10][11].

Group 1 - The company Shandong Weigao Blood Purification Products Co., Ltd. has received approval for its initial public offering (IPO) of A-shares and will be listed on the main board [1][2] - The total number of shares to be issued is 41,139,407 shares, with an initial strategic placement of 4,113,940 shares, accounting for 10% of the total issuance [2] - The final strategic placement amount is 1,772,075 shares, approximately 4.31% of the total issuance, leading to a total of 28,259,832 shares available for offline and online distribution [2][3] Group 2 - The IPO price is set at 26.50 yuan per share, with the initial issuance of 11,107,500 shares scheduled for May 8, 2025 [2][3] - The online subscription received an oversubscription rate of approximately 7,518.35 times, prompting the activation of a mechanism to adjust the allocation between offline and online investors [2][3] - After the adjustment, the final allocation is 12,512,832 shares for offline investors (31.78%) and 26,854,500 shares for online investors (68.22%) [3] Group 3 - The final online winning rate for investors is approximately 0.03215719% [3] - Investors are required to fulfill their payment obligations by May 12, 2025, and must ensure sufficient funds in their accounts [4] - The company has established a lock-up period of 6 months for 10% of the shares allocated to strategic placement investors, while 90% of the shares will be tradable immediately after listing [5][6] Group 4 - The strategic placement includes a special asset management plan for the company's senior management and core employees, managed by Huatai Securities [6][7] - The total amount of funds committed by strategic placement investors has been received in full by the underwriter [7] - The online lottery for share allocation was conducted on May 9, 2025, with a total of 53,709 winning numbers announced [8][9]